Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma

Two randomized trials of reirradiation after salvage surgery have been conducted by the GETTEC and GORTEC collaborative groups, both members of the French HN Intergroup: The first trial compared reirradiation and a "wait and see attitude" and was published in 2008 \[1\]. The second trial compared two modalities of reirradiation. Our hypothesis is that adjuvant treatment with immunotherapy will lead to a DFS similar to that observed in previous trials of post-operative reirradiation with possibly lower toxicity.

Trial Details

NCT ID
NCT03406247
Phase
PHASE2
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Nivolumab
  • Ipilimumab
Locations (sample)
  • Villejuif, Val De Marne, France|48.7939,2.35992

Key Eligibility Criteria

  • Recurrence or second primary of HNSCC in a previously irradiated area at a dose ≥ 50 Gys
  • HNSCC of oral cavity, oro and hypopharynx, larynx only if extralaryngeal spread (rT4), isolated nodal recurrence
  • Patient who has received salvage surgery with curative intent and macroscopic complete resection:
  • for cohorts 1 and 2: similarly to inclusion criteria of previous reirradiation trials, more than 6 months between radiotherapy and salvage surgery

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →